Physician profile
Thomas Piemonte
NPI 1225134067
$330,465.90
in general payments reported to CMS, 2019-2025
11 companies · $4,265 in 2025
The $4,265 reported for 2025 was more than what 81% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $78K · 2021: $22K · 2022: $83.65 · 2023: $5,397 · 2024: $188K · 2025: $4,265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $185K · Royalty Or License: $4,565 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,575 · Consulting Fee: $2,400 · Travel and Lodging: $1,508 · Food and Beverage: $1,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $185,258.86 |
| Royalty Or License | $4,565.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,575.00 |
| Consulting Fee | $2,400.00 |
| Travel and Lodging | $1,507.55 |
| Food and Beverage | $1,129.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $185,258.86 | 2024 | |
| Anika Therapeutics, INC. | $85,162.80 | 2020-2021 | |
| Abbott Laboratories | $48,599.78 | 2019-2025 | Amplatzer Talisman, Amplatzer, Navitor |
| Spirus Medical LLC | $8,148.93 | 2019-2025 | |
| Edwards Lifesciences Corporation | $1,951.63 | 2021-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Pascal, Sapien 3 Ultra Resilia |
| Primo Medical Group, INC. (F.K.A. Std Med INC.) | $1,125.00 | 2021 | |
| Medtronic, INC. | $135.26 | 2025 | Corevalve Evolut R |
| Chiesi USA, INC. | $83.64 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$618,670.80 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Piemonte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.